Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Olav Mella talks autoimmunity and metabolism in ME / CFS

It’s #OMFScienceWednesday! Today we share a video lecture by OMF Scientific Advisory Board member Dr. Olav Mella of the University of Bergen, Norway. In this lecture, Dr. Mella talks about the evidence for autoimmunity and metabolic disturbances in ME / CFS, and what such findings may mean for treatments. The lecture is in Norwegian but there are English subtitles available from the Closed Captions menu.

Dr. Mella made the following points:

  • Autoimmunity: It is clear that the immune system is involved in ME / CFS pathology, and he noted that while there is evidence for autoimmunity, ME / CFS does not behave like a ‘classical’ autoimmune disease;
  • Genetics: Evidence for genetic predisposition to ME / CFS has been presented in many studies, and his team is currently studying families to understand this better;
  • Cytokines: He believes that the many aberrations observed in cytokines – signalling molecules that can indicate inflammation – may reflect an underlying process involved in ME / CFS, but are unlikely to be the cause or hold the answers;
  • Rituximab: Dr. Mella’s team has been exploring rituximab as a possible treatment, because of the evidence that B cells are overactive in ME / CFS – depleting them with rituximab could have beneficial effects for patients. His most recent clinical trial with rituximab did not show significant improvements in the patient group he studied. He believes physicians should be cautious about recommending rituximab treatment, but he also believes there is a subgroup of patients in which rituximab would be effective. The challenge is that we have no marker for identifying these patients;
  • Cyclophosphamide: Dr. Mella’s most recent clinical trial with cyclophosphamide, which causes a more general immunosuppression, showed more promising preliminary results than that with rituximab. However, patients tolerate it less well – it causes nausea.

For more details, watch the video / read the transcript on YouTube.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669